azithromycin

Summary

Summary: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Top Publications

  1. Ray W, Murray K, Hall K, Arbogast P, Stein C. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-90 pubmed publisher
    ..several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity...
  2. Medina C, Rowe A, Yun H, Knickelbein J, Lathrop K, Hendricks R. Azithromycin treatment increases survival of high-risk corneal allotransplants. Cornea. 2013;32:658-66 pubmed publisher
    To test the therapeutic efficacy of azithromycin (AZM), a macrolide antibiotic for prolonging murine "high-risk" corneal allograft survival...
  3. Trivedi N, Shah P. A meta-analysis comparing the safety and efficacy of azithromycin over the alternate drugs used for treatment of uncomplicated enteric fever. J Postgrad Med. 2012;58:112-8 pubmed publisher
    ..A meta-analysis was planned to determine the strength of evidence supporting use of azithromycin over the alternate drugs available for treatment of uncomplicated typhoid fever...
  4. Gaynor B, Amza A, Kadri B, Nassirou B, Lawan O, Maman L, et al. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial. Am J Trop Med Hyg. 2014;90:846-51 pubmed publisher
    We assessed the effect of mass azithromycin treatment on malaria parasitemia in a trachoma trial in Niger. Twenty-four study communities received treatment during the wet, high-transmission season...
  5. Keenan J, See C, Moncada J, Ayele B, Gebre T, Stoller N, et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Invest Ophthalmol Vis Sci. 2012;53:235-40 pubmed publisher
    ..Organization (WHO) simplified grading system for trachoma to monitor the clinical response after repeated mass azithromycin treatments, the programmatic relevance of this evaluation after multiple rounds of antibiotic treatments is ..
  6. Hahn D, Grasmick M, Hetzel S, Yale S. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med. 2012;25:442-59 pubmed publisher
    ..performed a randomized, placebo-controlled, double-blinded effectiveness trial of 12 weekly doses of adjunctive azithromycin, with follow-up to 1 year after randomization, in adults with persistent asthma...
  7. Amza A, Kadri B, Nassirou B, Stoller N, Yu S, Zhou Z, et al. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. PLoS Negl Trop Dis. 2012;6:e1586 pubmed publisher
    Trachoma control programs utilize mass azithromycin distributions to treat ocular Chlamydia trachomatis as part of an effort to eliminate this disease world-wide...
  8. Mal P, Dutta K, Bandyopadhyay D, Basu A, Khan R, Bishayi B. Azithromycin in combination with riboflavin decreases the severity of Staphylococcus aureus infection induced septic arthritis by modulating the production of free radicals and endogenous cytokines. Inflamm Res. 2013;62:259-73 pubmed publisher
    To determine alternate therapeutic measures to combat Staphylococcus aureus induced arthritis. Thus, azithromycin was combined with riboflavin, which may combat the ROS production and inflammation.
  9. Laufer M, Thesing P, Dzinjalamala F, Nyirenda O, Masonga R, Laurens M, et al. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS ONE. 2012;7:e42284 pubmed publisher
    ..Participants were randomized to receive chloroquine alone or combined with artesunate, azithromycin or atovaquone-proguanil for all episodes of uncomplicated malaria for one year...

More Information

Publications62

  1. Chang A, Grimwood K, Robertson C, Wilson A, Van Asperen P, O Grady K, et al. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials. 2012;13:156 pubmed publisher
    ..Our study tests the hypothesis that both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo at improving resolution rates of respiratory ..
  2. Han M, Tayob N, Murray S, Dransfield M, Washko G, Scanlon P, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503-8 pubmed publisher
    Daily azithromycin decreases acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but long-term side effects are unknown...
  3. Pinto L, Pitrez P, Luisi F, de Mello P, Gerhardt M, Ferlini R, et al. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial. J Pediatr. 2012;161:1104-8 pubmed publisher
    To test the hypothesis that azithromycin reduces the length of hospitalization and oxygen requirement in infants with acute viral bronchiolitis (AB)...
  4. Twin J, Jensen J, Bradshaw C, Garland S, Fairley C, Min L, et al. Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. PLoS ONE. 2012;7:e35593 pubmed publisher
    ..The MG treatment failure rate using 1 g azithromycin at an Australian Sexual Health clinic in 2007-9 was 31% (95%CI 23-40%)...
  5. Muldoon E, Walsh A, Crowley B, Mulcahy F. Treponema pallidum azithromycin resistance in Dublin, Ireland. Sex Transm Dis. 2012;39:784-6 pubmed
    This study aimed to reassess rates of syphilis azithromycin resistance in Dublin. Of the 104 samples, 36 (34.6%) were positive for Treponema pallidum DNA by polymerase chain reaction...
  6. Chen X, Yin Y, Wei W, Wang H, Peng R, Zheng H, et al. High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China. Clin Microbiol Infect. 2013;19:975-9 pubmed publisher
    ..This study aimed to evaluate the prevalence of azithromycin resistance to T. pallidum in China...
  7. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368:1704-12 pubmed publisher
    b>Azithromycin use is associated with an increased risk of death from cardiovascular causes among patients at high baseline risk. Whether azithromycin confers a similar risk in the unselected general population is unknown...
  8. Lin S, Yan D, Lee W, Kuo M, Hsiao H, Lee P. Effect of azithromycin on natural killer cell function. Int Immunopharmacol. 2012;13:8-14 pubmed publisher
    b>Azithromycin (AZM), a macrolide antibiotic for treating mycoplasma infections, may exhibit anti-inflammatory activity aside from its antimicrobial effect, providing additional therapeutic benefit...
  9. Ssemanda E, Levens J, Mkocha H, Munoz B, West S. Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds. PLoS Negl Trop Dis. 2012;6:e1576 pubmed publisher
    ..We examined risk factors for households with at least one child who did not participate in two MDAs compared to households where all children participated in both MDAs...
  10. Pomares X, Montón C, Espasa M, Casabon J, Monso E, Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis. 2011;6:449-56 pubmed publisher
    The aim of this study was to determine whether long-term intermittent azithromycin therapy reduces the frequency of exacerbation in severe chronic obstructive pulmonary disease (COPD)...
  11. Saint Criq V, Ruffin M, Rebeyrol C, Guillot L, Jacquot J, Clement A, et al. Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells. Eur J Pharmacol. 2012;674:1-6 pubmed publisher
    ..Cystic fibrosis pulmonary pathophysiology is characterised by chronic inflammation and bacterial infections. Azithromycin, a macrolide antibiotic, has shown promising anti-inflammatory properties in some inflammatory pulmonary ..
  12. Starnino S, Galarza P, Carvallo M, Benzaken A, Ballesteros A, Cruz O, et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to cef. Sex Transm Dis. 2012;39:813-21 pubmed
    ..to 2009, aggregated ciprofloxacin resistance increased from 2% (19/784) to 31% (311/1015) in 9 countries and azithromycin resistance increased from 6% (39/646) to 23% (225/962) in 4/6 reporting countries...
  13. Nujić K, Banjanac M, Munić V, Polancec D, Erakovic Haber V. Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. Cell Immunol. 2012;279:78-86 pubmed publisher
    b>Azithromycin and chloroquine have been shown to exhibit anti-inflammatory activities in a number of cellular systems, but the mechanisms of these activities have still not been clarified unequivocally...
  14. Chen C, Chi K, Pillay A, Nachamkin E, Su J, Ballard R. Detection of the A2058G and A2059G 23S rRNA gene point mutations associated with azithromycin resistance in Treponema pallidum by use of a TaqMan real-time multiplex PCR assay. J Clin Microbiol. 2013;51:908-13 pubmed publisher
    ..A total of 129 specimens PCR positive for T. pallidum that were obtained from an azithromycin resistance surveillance study conducted in the United States were analyzed. Sixty-six (51...
  15. Luntamo M, Kulmala T, Cheung Y, Maleta K, Ashorn P. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. Trop Med Int Health. 2013;18:386-97 pubmed publisher
    ..and reproductive tract infections with monthly sulphadoxine-pyrimethamine (SP), alone or with two doses of azithromycin. We enrolled 1320 women with uncomplicated second trimester pregnancies into a randomised, partially placebo ..
  16. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7 pubmed publisher
    b>Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties...
  17. Campbell J, Mkocha H, Munoz B, West S. Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania. Ophthalmic Epidemiol. 2012;19:38-42 pubmed publisher
    To determine whether 2-day dosing of azithromycin may improve the efficacy of azithromycin dosing in children with severe trachoma.
  18. Grimes M, Sahi S, Godornes B, Tantalo L, Roberts N, Bostick D, et al. Two mutations associated with macrolide resistance in Treponema pallidum: increasing prevalence and correlation with molecular strain type in Seattle, Washington. Sex Transm Dis. 2012;39:954-8 pubmed publisher
    Although azithromycin promised to be a safe and effective single-dose oral treatment of early syphilis, azithromycin treatment failure has been documented and is associated with mutations in the 23S rDNA of corresponding Treponema ..
  19. Foulks G, Borchman D, YAPPERT M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32:44-53 pubmed publisher
    ..documents the improvement in both clinical signs and symptoms of disease as well as spectroscopic characteristics of the meibomian gland lipids after therapy with topical azithromycin ophthalmic solution and oral doxycycline treatment.
  20. Metzler K, Drlica K, Blondeau J. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2013;68:631-5 pubmed publisher
    Previous work showed a higher prevalence of macrolide/azalide resistance in provinces of Canada where azithromycin was the major treatment for Streptococcus pneumoniae as compared with regions where clarithromycin was the dominant ..
  21. Southern K, Barker P, Solis Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012;11:CD002203 pubmed publisher
    ..Ten of 31 studies identified were included (959 patients). Five studies with a low risk of bias examined azithromycin versus placebo and demonstrated consistent improvement in forced expiratory volume in one second over six ..
  22. Grigsby P, Novy M, Sadowsky D, Morgan T, Long M, Acosta E, et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol. 2012;207:475.e1-475.e14 pubmed publisher
    We assessed the efficacy of a maternal multidose azithromycin (AZI) regimen, with and without antiinflammatory agents to delay preterm birth and to mitigate fetal lung injury associated with Ureaplasma parvum intraamniotic infection...
  23. Garnock Jones K. Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. Drugs. 2012;72:361-73 pubmed publisher
    The second-generation macrolide azithromycin is available as a 1.5% ophthalmic solution for use in the treatment of bacterial or trachomatous conjunctivitis. This article reviews the pharmacological properties of azithromycin 1...
  24. Hodge S, Reynolds P. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology. 2012;17:802-7 pubmed publisher
    ..We have previously shown that administration of low-dose azithromycin to subjects with COPD improved macrophage phagocytosis of apoptotic airway epithelial cells, reduced ..
  25. Mitjà O, Hays R, Ipai A, Penias M, Paru R, Fagaho D, et al. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. Lancet. 2012;379:342-7 pubmed publisher
    ..Oral azithromycin is effective for syphilis...
  26. Berkhof F, Boom L, Ten Hertog N, Uil S, Kerstjens H, van den Berg J. The validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic cough. Health Qual Life Outcomes. 2012;10:4 pubmed publisher
    ..We examined the psychometric performance of the LCQ in patients with COPD and chronic productive cough...
  27. Ghanem K, Workowski K. Management of adult syphilis. Clin Infect Dis. 2011;53 Suppl 3:S110-28 pubmed publisher
    ..Although additional data on the efficacy of azithromycin in treating early syphilis have emerged, reported increases in the prevalence of a mutation associated with ..
  28. Gesink D, Mulvad G, Montgomery Andersen R, Poppel U, Montgomery Andersen S, Binzer A, et al. Mycoplasma genitalium presence, resistance and epidemiology in Greenland. Int J Circumpolar Health. 2012;71:1-8 pubmed publisher
    ..Greenland reports the highest rates of chlamydial infection and gonorrhea in the Arctic. Our objective was to determine the presence, and describe the basic epidemiology, of Mycoplasma genitalium for Greenland...
  29. Banerjee B, Musk M, Sutanto E, Yerkovich S, Hopkins P, Knight D, et al. Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin. PLoS ONE. 2012;7:e52309 pubmed publisher
    ..The macrolide antibiotic azithromycin and the DNA synthesis inhibitor mycophenolate are in clinical use but their mechanism of action remains unknown ..
  30. Kauss T, Gaubert A, Boyer C, Ba B, Manse M, Massip S, et al. Pharmaceutical development and optimization of azithromycin suppository for paediatric use. Int J Pharm. 2013;441:218-26 pubmed publisher
    ..process optimization work was undertaken in order to propose a potential paediatric rectal formulation of azithromycin as an alternative to existing oral or injectable formulations...
  31. Harding Esch E, Sillah A, Edwards T, Burr S, Hart J, Joof H, et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis. 2013;7:e2115 pubmed publisher
    ..The best way to treat these districts, and the optimum role of testing for infection in deciding whether to initiate or discontinue MDA, are unknown...
  32. Peng J, Hou C, Liu X, Li H, Hu X. Electrochemical behavior of azithromycin at graphene and ionic liquid composite film modified electrode. Talanta. 2011;86:227-32 pubmed publisher
    An electrochemical method has been successfully demonstrated for sensitive determination of azithromycin (Azi) with room temperature ionic liquid (IL) of 1-butyl-3-methylimidazolium hexafluorophosphate (BMIMPF(6)) - graphene (Gr) ..
  33. Bauer K, Brimhall A, Chang T. Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with azithromycin in acute Epstein-Barr virus infection. Pediatr Dermatol. 2011;28:741-3 pubmed publisher
    We report the first pediatric case of drug reaction with eosinophilia and systemic symptoms associated with azithromycin use in the setting of acute Epstein-Barr virus infection in an 8-year-old boy...
  34. Amza A, Kadri B, Nassirou B, Stoller N, Yu S, Zhou Z, et al. A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in Niger. Am J Trop Med Hyg. 2013;88:138-43 pubmed publisher
    ..we assess anthropometry measurements in children 6-60 months in 24 communities randomized to one or two mass azithromycin distributions over a 1-year period in Niger...
  35. Marvig R, Søndergaard M, Damkiær S, Høiby N, Johansen H, Molin S, et al. Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:4519-21 pubmed publisher
    ..In this study, we report the occurrence of azithromycin resistance among clinical P. aeruginosa DK2 isolates...
  36. . Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis. 2012;39:794-8 pubmed
    ..The 23S rRNA A2058G point mutation in Treponema pallidum is associated with macrolide antibiotic treatment failure. Its prevalence and potential association with a molecular subtype within the United States are unknown...
  37. Buyck J, Plesiat P, Traore H, Vanderbist F, Tulkens P, Van Bambeke F. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis. 2012;55:534-42 pubmed publisher
    ..Nevertheless, azithromycin is successfully used in cystic fibrosis patients, supposedly because of "nonantibiotic effects...
  38. Labbe A, Pepin J, Khonde N, Dzokoto A, Méda H, Asamoah Adu C, et al. Periodical antibiotic treatment for the control of gonococcal and chlamydial infections among sex workers in Benin and Ghana: a cluster-randomized placebo-controlled trial. Sex Transm Dis. 2012;39:253-9 pubmed publisher
    ..one was allocated to receive, during 9 months, a monthly antibiotic (alternatively ciprofloxacin or azithromycin, n = 296 FSWs) and the other a placebo (n = 340 FSWs)...
  39. Balaskas K, Vaudaux J, Boillat Blanco N, Guex Crosier Y. Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit. 2012;18:CR296-302 pubmed
    The purpose of this pilot study is to compare the efficacy and tolerance of azithromycin alone as opposed to standard treatment with sulfadiazine and pyrimethamine for active, non-vision-threatening toxoplasmic retinochoroiditis...
  40. Coles C, Levens J, Seidman J, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J. 2012;31:341-6 pubmed publisher
    We evaluated the effect of a single mass distribution of azithromycin for trachoma on the risk of acute lower respiratory infection (ALRI) during a 6-month period among young children living in 8 communities in rural Tanzania...
  41. Berkhof F, Doornewaard ten Hertog N, Uil S, Kerstjens H, van den Berg J. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res. 2013;14:125 pubmed publisher
    ..Their effects on health status has not been assessed as primary outcome and is less clear. This study assessed the effects of prophylactic azithromycin on cough-specific health status in COPD-patients with chronic productive cough.
  42. Luntamo M, Rantala A, Meshnick S, Cheung Y, Kulmala T, Maleta K, et al. The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial. PLoS ONE. 2012;7:e41123 pubmed publisher
    ..The participants received SP twice (controls), monthly SP, or monthly SP and two doses of azithromycin (AZI-SP)...
  43. Coles C, Mabula K, Seidman J, Levens J, Mkocha H, Munoz B, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis. 2013;56:1519-26 pubmed publisher
    Emerging evidence suggests that the mass distribution of azithromycin for trachoma control (MDA) may increase circulation of macrolide resistance in bacteria associated with severe pediatric infections in treated communities.
  44. Mergenhagen K, Olbrych P, Mattappallil A, Krajewski M, Ott M. Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin. Clin Ther. 2013;35:425-30 pubmed publisher
    ..The incidence of overanticoagulation in patients prescribed azithromycin stabilized on a warfarin regimen is controversial...
  45. Vos R, Vanaudenaerde B, Verleden S, Ruttens D, Vaneylen A, Van Raemdonck D, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation. 2012;94:101-9 pubmed publisher
    ..However, the introduction of the neomacrolide antibiotic azithromycin (AZI) in the field of LTx as of 2003 made it clear that some patients with established BOS might in fact ..
  46. Nitschke M, Sayk F, Hartel C, Roseland R, Hauswaldt S, Steinhoff J, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA. 2012;307:1046-52 pubmed publisher
    ..In the German outbreak, a substantial number of patients received prophylactic azithromycin treatment as part of a therapeutic regimen with the C5 antibody eculizumab...
  47. Chini P, Toskes P, Waseem S, Hou W, McDonald R, Moshiree B. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol. 2012;47:422-7 pubmed publisher
    To investigate the effect of azithromycin (AZI) on small bowel activity in patients with gastrointestinal dysmotility (GID). Manometric data on a consecutive series of 21 patients was reviewed...
  48. Fernando S, Molland J, Gottlieb T. Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused by Salmonella enterica serotype Paratyphi A. Pathog Glob Health. 2012;106:366-9 pubmed publisher
    ..abscesses, resistant to ciprofloxacin, which relapsed despite surgery, aspiration and multiple courses of antibiotics, including co-trimoxazole and azithromycin. The patient was cured after a prolonged course of intravenous ceftriaxone.
  49. Ensafi A, Allafchian A, Rezaei B. A sensitive and selective voltammetric sensor based on multiwall carbon nanotubes decorated with MgCr?O? for the determination of azithromycin. Colloids Surf B Biointerfaces. 2013;103:468-74 pubmed publisher
    ..decorated with MgCr(2)O(4) nanoparticles were used as a new mediator for voltammetric determination of azithromycin. The oxidation peak of azithromycin was appeared at a potential of about 720 mV at a surface of the modified ..
  50. Rosenberg A, Rosenkrantz W, Griffin C, Angus J, Keys D. Evaluation of azithromycin in systemic and toothpaste forms for the treatment of ciclosporin-associated gingival overgrowth in dogs. Vet Dermatol. 2013;24:337-45, e74-5 pubmed publisher
    Gingival overgrowth is an adverse effect of ciclosporin therapy. Azithromycin (AZI) in capsule and toothpaste form is an effective treatment for ciclosporin-associated gingival overgrowth (CsAGO) in humans.
  51. Togami K, Chono S, Morimoto K. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Pharmazie. 2012;67:389-93 pubmed
    ..highly distributes from plasma to lung epithelium lining fluid (ELF), the infection site of pathogens, than azithromycin (AZM) and telithromycin (TEL)...
  52. Yeruva L, Melnyk S, Spencer N, Bowlin A, Rank R. Differential susceptibilities to azithromycin treatment of chlamydial infection in the gastrointestinal tract and cervix. Antimicrob Agents Chemother. 2013;57:6290-4 pubmed publisher
    ..To determine the effect of azithromycin on persistent chlamydial gut infection, C57BL/6 and BALB/c mice were infected orally and genitally and treated ..
  53. Hottes T, Lester R, Hoang L, McKay R, Imperial M, Gilbert M, et al. Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis. 2013;40:46-51 pubmed publisher
    ..has challenged effective treatment and control; recent international case reports of cefixime, ceftriaxone, and azithromycin resistance suggest that the remaining treatment options are now additionally threatened...